// App-Quantinova.ai

P402 : Incidence and outcomes of herpes zoster in the ozanimod phase 3 ulcerative colitis and relapsing multiple sclerosis clinical program

Researchers

Presenter

  • Siegmund, B

Principal Investigators

  • Melmed, G.Y

  • Irving, P.M

  • Pai, A

  • Patel, A

  • Sheffield, J.K

  • Caldera, F

  • Cree, B.A.C

  • Dubinsky, M.C

Medical Centers

  • CharitA Universitatsmedizin Berlin, Gastroenterologie/Infektiologie/Rheumatologie, Berlin, Germany

  • Cedars-Sinai Medical Center, Medicine, Los Angeles, United States

  • Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom

  • Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States

  • University of Wisconsin-Madison School of Medicine and Public Health, Gastroenterology, Madison, United States

  • University of California San Francisco, Gastroenterology, San Francisco, United States

  • Mount Sinai Hospital, Gastroenterology, New-York, United States

Locations

  • Germany

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Autoimmune (AI)

  • Infectious Diseases (ID)

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

  • Ulcerative colitis

  • Shingles

  • Lymphocytopenia

Biomarkers

  • Immunoglobulin G

  • Sphingosine-1-phosphate

Drug/Treatment

  • Ozanimod

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved